Business Context and Reporting Period
Company: Contineum Therapeutics, Inc. (CTNM)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2024
Reporting Period: The filing announces financial results for the quarter ended September 30, 2024, and provides a corporate update.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for these metrics.
Material Changes
The filing indicates the issuance of a press release regarding Q3 2024 results and a corporate update. No specific material changes or comparative data versus prior periods are detailed in the text provided.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on November 6, 2024, containing a corporate update and financial results.
Legal Status: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into registration statements unless specifically identified.
Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 6, 2024) for specific Q3 2024 financial figures.
- Verify the details of the "corporate update" mentioned in the press release.
- Confirm the Company's status as an emerging growth company and any associated accounting election implications.
- Check for any subsequent filings that may incorporate the press release by reference.